Old Web
English
Sign In
Acemap
>
authorDetail
>
Philippe Giguere-Duval
Philippe Giguere-Duval
Analysis Group
Medicine
Internal medicine
Immunology
Imatinib
Chronic myelogenous leukemia
4
Papers
5
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Do oncology patients in an outpatient hospital receive the same care as patients in an office/clinic setting? A case study evaluating patients with non-metastatic HER2+ breast cancer (BC) receiving adjuvant trastuzumab.
2017
Journal of Clinical Oncology
Deepa Lalla
Melissa Brammer
Annie Guerin
Geneviève Gauthier
Philippe Giguere-Duval
Eric Q. Wu
Eduardo Santos
Show All
Source
Cite
Save
Citations (0)
Comparison of discontinuation, health care resource utilization (HRU), and costs between metastatic breast cancer (mBC) patients (pts) who received trastuzumab (T) in an office clinic versus outpatient hospital setting.
2017
Journal of Clinical Oncology
Melissa Brammer
Deepa Lalla
Geneviève Gauthier
Annie Guerin
Philippe Giguere-Duval
Eric Q. Wu
Eduardo Santos
Show All
Source
Cite
Save
Citations (0)
Impact of timely switching from imatinib to a second-generation tyrosine kinase inhibitor after 12-month complete cytogenetic response failure: a chart review analysis.
2014
Clinical Lymphoma, Myeloma & Leukemia
Daniel J. DeAngelo
Lei Chen
Annie Guerin
Amy Styles
Philippe Giguere-Duval
Eric Q. Wu
Show All
Source
Cite
Save
Citations (5)
Benefits of Early Switching From Imatinib to a Second-Generation Tyrosine Kinase Inhibitor Following 12 Month Complete Cytogenetic Response Failure: A Chart Review Analysis.
2012
Blood
Daniel J. DeAngelo
Lei Chen
Annie Guerin
Amy Styles
Clemence Aberki
Philippe Giguere-Duval
Eric Q. Wu
Show All
Source
Cite
Save
Citations (0)
1